Literature DB >> 30073584

Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders.

Michael J Marmura1, Aliza S Kumpinsky2.   

Abstract

Anti-epileptic drugs are among the most effective drugs for migraine prophylaxis, and will likely continue to have a role even as new therapies emerge. Topiramate and valproate are effective for the preventive treatment of migraine, and other medications such as gabapentin or lamotrigine may have a role in the treatment of those with allodynia or frequent aura, respectively. Oxcarbazepine, carbamazepine, phenytoin, gabapentin, and others may alleviate pain in trigeminal neuralgia. While many anti-epileptic drugs can be effective in those with migraine or other headaches, most of these agents can potentially cause serious side effects. In particular, valproate, topiramate, carbamazepine, and phenytoin may lead to adverse outcomes for infants of exposed mothers. Valproate should not be given to women of childbearing potential for migraine prevention.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30073584     DOI: 10.1007/s40263-018-0555-z

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  116 in total

1.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

2.  Canadian Headache Society guideline for migraine prophylaxis.

Authors:  Tamara Pringsheim; W Jeptha Davenport; Gordon Mackie; Irene Worthington; Michel Aubé; Suzanne N Christie; Jonathan Gladstone; Werner J Becker
Journal:  Can J Neurol Sci       Date:  2012-03       Impact factor: 2.104

Review 3.  Topiramate in Migraine Prevention: A 2016 Perspective.

Authors:  Stephen D Silberstein
Journal:  Headache       Date:  2016-11-30       Impact factor: 5.887

4.  Suppression of cortical spreading depression in migraine prophylaxis.

Authors:  Cenk Ayata; Hongwei Jin; Chiho Kudo; Turgay Dalkara; Michael A Moskowitz
Journal:  Ann Neurol       Date:  2006-04       Impact factor: 10.422

Review 5.  Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms.

Authors:  Paolo Calabresi; Francesca Galletti; Cristiana Rossi; Paola Sarchielli; Letizia M Cupini
Journal:  Trends Pharmacol Sci       Date:  2007-03-06       Impact factor: 14.819

6.  Migraine preventive medication reduces resource utilization.

Authors:  Stephen D Silberstein; Paul K Winner; Joseph J Chmiel
Journal:  Headache       Date:  2003-03       Impact factor: 5.887

7.  Topiramate improves health-related quality of life when used to prevent migraine.

Authors:  Merle Diamond; Carl Dahlöf; George Papadopoulos; Walter Neto; S-C Wu
Journal:  Headache       Date:  2005-09       Impact factor: 5.887

Review 8.  Research advances in basic mechanisms of seizures and antiepileptic drug action.

Authors:  Władysław Lasoń; Małgorzata Chlebicka; Konrad Rejdak
Journal:  Pharmacol Rep       Date:  2013       Impact factor: 3.024

9.  Effect of preventive treatment on health-related quality of life in episodic migraine.

Authors:  Carlos A Bordini; Hilton Mariano da Silva; Roberta P Garbelini; Simone O Teixeira; José G Speciali
Journal:  J Headache Pain       Date:  2005-08-01       Impact factor: 7.277

Review 10.  Cortical spreading depression as a target for anti-migraine agents.

Authors:  Cinzia Costa; Alessandro Tozzi; Innocenzo Rainero; Letizia Maria Cupini; Paolo Calabresi; Cenk Ayata; Paola Sarchielli
Journal:  J Headache Pain       Date:  2013-07-23       Impact factor: 7.277

View more
  2 in total

Review 1.  Pharmacogenetics in Primary Headache Disorders.

Authors:  Irina I Belyaeva; Anna G Subbotina; Ivan I Eremenko; Vadim V Tarasov; Vladimir N Chubarev; Helgi B Schiöth; Jessica Mwinyi
Journal:  Front Pharmacol       Date:  2022-02-10       Impact factor: 5.810

Review 2.  Headache in people with epilepsy.

Authors:  Prisca R Bauer; Else A Tolner; Mark R Keezer; Michel D Ferrari; Josemir W Sander
Journal:  Nat Rev Neurol       Date:  2021-07-26       Impact factor: 42.937

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.